Table 1.
Infecting HIV clades and ELISA reactivity of plasma antibodies to Env antigens of patients with and without V2 antibodies
| MDC donors | HIV-1 | V1V21 | V1V21 | V1V21 | V2pept2 | V2pept2 | V2pept2 | V2pept2,3 | V2pept2,3 | V3pept2 | gp120 | gp41 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A244 | CaseA2 | ZM109 | A244 | TH023 | Du422 | 230 | 200 | A244 | A244 | MN | ||
| AE | B | C | AE | AE | C | AG | AG | AE | AE | B | ||
| 230-1 | CRF02_AG | 3.6 | 3.5 | 2.4 | 3.6 | 2.9 | 3.5 | 3.5 | 0.8 | 3.5 | 3.2 | 3.4 |
| 6501-6 | CRF02_AG | 3.5 | 2.2 | 3.6 | 3.5 | 2.2 | 3.0 | 2.1 | 1.3 | 3.1 | 3.5 | 2.9 |
| 221-2 | CRF01_AE | 2.1 | 2.3 | 2.2 | 3.3 | 1.9 | 3.0 | 3.0 | 0.4 | 3.7 | 3.8 | 3.3 |
| 237-2 | CRF11_cpx | 2.4 | 3.3 | 2.2 | 3.6 | 1.9 | 1.4 | 0.7 | 1.6 | 3.6 | 4.0 | 3.2 |
| 001-4 | CRF18_cpx | 3.2 | 3.1 | 2.0 | 3.5 | 3.5 | 3.5 | 3.5 | 0.3 | 3.6 | 3.9 | 2.9 |
| 060-2 | CRF36_cpx | 2.6 | 3.3 | 2.5 | 2.6 | 1.1 | 1.7 | 2.3 | 0.8 | 3.6 | 3.3 | 3.5 |
| 200-2 | CRF02_AG | 0.1 | 0.2 | 0.3 | 0.3 | 0.3 | 0.5 | 0.3 | 1.4 | 2.9 | 3.2 | 3.4 |
| 122-3 | CRF01_AE | 0.5 | 0.3 | 0.2 | 0.3 | 0.2 | 0.2 | 0.3 | 0.2 | 3.6 | 3.9 | 3.5 |
| 019-3 | CRF22_01A1 | 0.2 | 0.2 | 0.4 | 0.2 | 0.3 | 0.3 | 0.3 | 0.1 | 3.8 | 1.8 | 3.0 |
| 211-1 | CRF22_01A1 | 0.3 | 0.4 | 0.4 | 0.3 | 0.2 | 0.2 | 0.3 | 0.1 | 3.0 | 3.0 | 3.3 |
| 195-3 | CRF37_cpx | 0.4 | 0.2 | 0.2 | 1.0 | 0.2 | 0.5 | 0.1 | 0.1 | 3.8 | 3.4 | 3.2 |
| 014-2 | C | 0.4 | 0.5 | 0.5 | 0.4 | 0.7 | 0.3 | 0.4 | 0.2 | 1.5 | 1.7 | 2.6 |
1
V1V2 – V1V2 fusion protein, HIV-1 strain and subtype;
2
V2 and V3pept. – Biotinylated cyclic peptides;
3
V2 peptides with sequences from virus of donor’s plasma: MDC230-1 and MDC200-2 (this allows testing of two plasma Abs vs. autologous antigens).
Plasma samples were screened by standard ELISA at 1:100 dilution against antigens coated at 1 μg/mL; biotinylated cyclic V2 and V3 peptides were immobilized at 1 μg/mL on the streptavidin coated plates. The values bold are above cutoff (mean OD of 6 control healthy plasma samples + 3 standard deviation).